TRL Trilogy International Partners Inc

EDISON EQUITY RESEARCH: TRIMEL PHARMACEUTICALS - TRT UNDER FDA SPOTLIGHT

A joint panel of two FDA advisory committees voted in September to modify the labelling of TRT products to curtail usage when clinical benefit may not be definitive. While it is unclear how the FDA will respond, we believe that end-user demand for TRT will largely persist and that Natesto’s novel delivery should generate interest when launched in H115.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is being marketed for HRT in Canada.

To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals5


Click here to view all of Edison Investment Research’s published reports